A comprehensive view of Phase 3 Trial. This page highlights a small sample of our full coverage.
For real-time access, please log in to your R&D/Patents Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia
Published: April 23, 2024 by Sanofi SA
Health Canada approves Merck & Co's KEYTRUDA in combination with chemotherapy for advanced gastric or gastroesophageal junction adenocarcinoma treatment following successful Phase 3 trial
Published: April 19, 2024 by EquityBites
Phase 3 study of Roche's OCREVUS subcutaneous injection shows near-complete suppression of multiple sclerosis relapse activity and lesions; approval anticipated from FDA and EMA in 2024
Published: April 17, 2024 by F. Hoffmann-La Roche Ltd. (Roche)
Eli Lilly reports tirzepatide injectable significantly reduced sleep apnea in Phase 3 trials, achieving up to 63% reduction in the apnea-hypopnea index, a measure of sleep apnea severity; the drug also led to significant weight loss
Published: April 17, 2024 by Eli Lilly & Co.
AstraZenica's Imfinzi plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 Phase 3 trial
Published: April 16, 2024 by AstraZeneca AB

Ask us about our R&D/Patents market view

Trending Chart

Interactive chart with headline count